InVitae Corp (NVTA) Shares Bought by Verity Asset Management Inc.
Verity Asset Management Inc. grew its stake in shares of InVitae Corp (NYSE:NVTA) by 120.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,186 shares of the medical research company’s stock after purchasing an additional 13,740 shares during the quarter. Verity Asset Management Inc.’s holdings in InVitae were worth $174,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Teacher Retirement System of Texas acquired a new position in shares of InVitae in the 4th quarter valued at $116,000. Lakeview Capital Partners LLC acquired a new position in shares of InVitae in the 3rd quarter valued at $117,000. Gabelli Funds LLC acquired a new position in shares of InVitae in the 3rd quarter valued at $131,000. State Board of Administration of Florida Retirement System acquired a new position in shares of InVitae in the 3rd quarter valued at $133,000. Finally, CAPROCK Group Inc. acquired a new position in shares of InVitae in the 3rd quarter valued at $139,000. 65.12% of the stock is currently owned by institutional investors.
InVitae Corp (NVTA) opened at $6.02 on Tuesday. The company has a market cap of $333.03 and a price-to-earnings ratio of -2.47. InVitae Corp has a 1-year low of $3.80 and a 1-year high of $10.41. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.61 and a quick ratio of 2.61.
A number of equities analysts have recently commented on NVTA shares. Ladenburg Thalmann Financial Services started coverage on shares of InVitae in a report on Friday, January 5th. They issued a “buy” rating and a $15.00 target price on the stock. Benchmark cut their target price on shares of InVitae from $16.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, January 16th. BidaskClub cut shares of InVitae from a “buy” rating to a “hold” rating in a report on Thursday, October 26th. Zacks Investment Research cut shares of InVitae from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 17th. Finally, Leerink Swann cut their target price on shares of InVitae from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday, January 16th. Three analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. InVitae has a consensus rating of “Hold” and a consensus target price of $12.40.
ILLEGAL ACTIVITY WARNING: This story was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://theolympiareport.com/2018/02/13/invitae-corp-nvta-shares-bought-by-verity-asset-management-inc.html.
InVitae Company Profile
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Want to see what other hedge funds are holding NVTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InVitae Corp (NYSE:NVTA).
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.